2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Maha Hussain, MD, Professor of Medicine and Urology, University of Michigan, associate director, Clinical Research, co-leader, Prostate Cancer/GU Oncology Program, assistant chief, Clinical Research at the Division of Hematology/ Oncology, University of Michigan Comprehensive Cancer Center, discusses new therapeutic approaches in castration-resistance prostate cancer.
There are several agents currently being tested targeting different aspect of the androgen-receptor in the setting of castration-resistance prostate cancer. Some drugs target the androgen-receptor itself, others target different sources of androgen, and there are also hybrid approaches, said Maha.
Whether or not it is better to have a multi-targeted approach remains unknown, said Maha.
Related Content: